Biomarkers for Managing Neurodegenerative Diseases
Neurological disorders are the leading cause of cognitive and physical disability worldwide,
affecting 15% of the global population. Due to the demographics of aging, the prevalence of …
affecting 15% of the global population. Due to the demographics of aging, the prevalence of …
Unraveling the Heterogeneity of ALS—A Call to Redefine Patient Stratification for Better Outcomes in Clinical Trials
L Tzeplaeff, AV Jürs, C Wohnrade, AF Demleitner - Cells, 2024 - mdpi.com
Despite tremendous efforts in basic research and a growing number of clinical trials aiming
to find effective treatments, amyotrophic lateral sclerosis (ALS) remains an incurable …
to find effective treatments, amyotrophic lateral sclerosis (ALS) remains an incurable …
[HTML][HTML] Limbic Network and Papez Circuit Involvement in ALS: Imaging and Clinical Profiles in GGGGCC Hexanucleotide Carriers in C9orf72 and C9orf72-Negative …
F Christidi, J Kleinerova, EL Tan, S Delaney… - Biology, 2024 - ncbi.nlm.nih.gov
Background: While frontotemporal involvement is increasingly recognized in Amyotrophic
lateral sclerosis (ALS), the degeneration of limbic networks remains poorly characterized …
lateral sclerosis (ALS), the degeneration of limbic networks remains poorly characterized …
Current potential diagnostic biomarkers of amyotrophic lateral sclerosis
Z Xu, R Xu - Reviews in the Neurosciences, 2024 - degruyter.com
Amyotrophic lateral sclerosis (ALS) currently lacks the useful diagnostic biomarkers. The
current diagnosis of ALS is mainly depended on the clinical manifestations, which …
current diagnosis of ALS is mainly depended on the clinical manifestations, which …
Corneal nerves and amyotrophic lateral sclerosis: an in vivo corneal confocal imaging study
RK Khanna, S Catanese, H Blasco, PJ Pisella… - Journal of …, 2024 - Springer
Objectives Amyotrophic lateral sclerosis (ALS) is a severe motor neuron disorder. Diagnosis
is challenging due to its clinical heterogeneity and the absence of definitive diagnostic tools …
is challenging due to its clinical heterogeneity and the absence of definitive diagnostic tools …
[HTML][HTML] Harnessing Big Data in Amyotrophic Lateral Sclerosis: Machine Learning Applications for Clinical Practice and Pharmaceutical Trials
EL Tan, J Lope, P Bede - Journal of Integrative Neuroscience, 2024 - imrpress.com
The arrival of genotype-specific therapies in amyotrophic lateral sclerosis (ALS) signals the
dawn of precision medicine in motor neuron diseases (MNDs). After decades of academic …
dawn of precision medicine in motor neuron diseases (MNDs). After decades of academic …
Cardiac troponin T as a serum biomarker of respiratory impairment in amyotrophic lateral sclerosis
T Koch, R Fabian, L Weinhold, FW Koch… - Annals of Clinical and … - Wiley Online Library
Objective Informative biomarkers are an urgent need in the management of amyotrophic
lateral sclerosis. Serum cardiac troponin T is elevated in the majority of amyotrophic lateral …
lateral sclerosis. Serum cardiac troponin T is elevated in the majority of amyotrophic lateral …